{"id":55656,"date":"2022-12-14T08:42:13","date_gmt":"2022-12-14T13:42:13","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=55656"},"modified":"2024-10-25T11:00:56","modified_gmt":"2024-10-25T15:00:56","slug":"bevespi-alternatives","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/bevespi-alternatives\/","title":{"rendered":"Bevespi alternatives: What can I take instead of Bevespi?"},"content":{"rendered":"

Bevespi Aerosphere is an inhaled brand-name prescription drug product used in the maintenance treatment of <\/span>chronic obstructive pulmonary disease (COPD)<\/span><\/a>. It is the combination of two drugs, glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta-agonist (LABA). Although they work via their own distinct mechanisms, LAMAs and LABAs ultimately lead to bronchodilation, or an opening and broadening of the airways. Bevespi is not approved by the Food and Drug Administration (FDA) for the treatment of asthma.<\/span><\/p>\n

Effective treatment of COPD is an important factor to many. In the United States alone, COPD is estimated to affect <\/span>. It is the fourth leading cause of disability in the United States according to the Centers for Disease Control and Prevention (CDC), and this has effects on society as a whole including the workforce and healthcare system.<\/span><\/p>\n

So what is COPD? COPD is comprised of two conditions, and most people who have COPD display symptoms of both to some varying extent. The first condition is emphysema. Your lungs have many air sacs, and the functionality of them is to contract and expand to move air. The walls of the sacs need to be “stretchy” and healthy in order for this to occur. In emphysema, these sac walls become damaged, and they can no longer contract and expand effectively to move air efficiently. The second condition of COPD is chronic bronchitis. This is characterized by constant irritation and inflammation of the lining of the airways. The presence of thick mucus makes it hard to move air in and through the airways.<\/span><\/p>\n

There is no cure for COPD. It can prevent even the most basic of life functions like walking, cooking, or bathing. Fortunately, the <\/span>symptoms of COPD<\/span><\/a> can often be managed with medications like Bevespi and allow people to live relatively normal lives with COPD along with other healthy lifestyle changes.<\/span><\/p>\n

The manufacturer of <\/span>Bevespi<\/span><\/a>, AstraZeneca, trialed the combination of glycopyrrolate and formoterol after evaluating the results of each drug on COPD symptoms alone. Bevespi consistently provided better results measured by forced expiratory volume (FEV) as compared to each drug component used alone or as compared to a placebo. Patients on Bevespi also had to use short-acting rescue bronchodilator inhalers like albuterol less frequently.<\/span><\/p>\n

There are some patients for whom Bevespi may not be the ideal choice. Though COPD doesn’t typically affect children, Bevespi is not indicated for children or women who are pregnant or breastfeeding. Bevespi should be used cautiously in those with impaired kidney or liver function. Glycopyrrolate is an anticholinergic drug, and this means that there are patients with some conditions where glycopyrrolate should be avoided or used cautiously. These include those with narrow-angle glaucoma, hyperthyroidism, seizure disorder, urinary retention, or chronic urinary tract infections. Formoterol and glycopyrrolate can have negative effects on pre-existing cardiovascular conditions as well, and those should be monitored closely if your doctor chooses to try Bevespi.<\/span><\/p>\n

Price is always a consideration as well. The manufacturer of Bevespi does offer a savings card, however, the price of Bevespi before insurance approaches $500 per month, and this may make Bevespi unattainable for many. If you are concerned that Bevespi isn’t the best choice for you, keep reading. There are other treatment options to discuss with your doctor.<\/span><\/p>\n

What can I take in place of Bevespi?<\/span><\/h2>\n

There are other treatment options if Bevespi isn’t the right one for you. These include other single drug and combination drug inhalers as well as oral medications. Generally speaking, drugs used in COPD are aimed to either open the airways, decrease mucus production, decrease airway inflammation, or decrease systemic inflammation. This isn’t intended to be medical advice. Your doctor or healthcare provider can evaluate your specific symptoms to determine which treatment options are most appropriate for you.<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Compare Bevespi alternatives<\/span><\/h2>\n<\/th>\n<\/tr>\n<\/thead>\n

Drug name<\/b><\/td>\nUses<\/b><\/td>\nDosage<\/b><\/td>\nSavings options<\/b><\/td>\n<\/tr>\n
Bevespi (glycopyrrolate\/ formoterol)<\/span><\/td>\nCOPD maintenance treatment<\/span><\/td>\n2 puffs (9\/ 4.8 mcg each) twice daily in the morning and evening<\/span><\/td>\nBevespi coupons<\/span><\/a><\/td>\n<\/tr>\n
Symbicort (budesonide\/ formoterol)<\/span><\/td>\nAsthma maintenance treatment, Chronic obstructive pulmonary disease (COPD)<\/span><\/td>\n2 puffs (80\/4.5 or 160\/4.5 mcg) inhaled by mouth twice daily<\/span><\/td>\nSymbicort coupons<\/span><\/a><\/td>\n<\/tr>\n
Breo Ellipta (fluticasone\/ vilanterol)<\/span><\/td>\nAsthma maintenance treatment, Chronic obstructive pulmonary disease (COPD)<\/span><\/td>\n1 inhalation (100\/25 mcg) by mouth once daily<\/span><\/td>\nBreo Ellipta coupons<\/span><\/a><\/td>\n<\/tr>\n
Anoro Ellipta (umeclidinium\/ vilanterol)<\/span><\/td>\nCOPD maintenance treatment<\/span><\/td>\n1 actuation (62.5\/25 mcg) by mouth once daily<\/span><\/td>\nAnoro coupons<\/span><\/a><\/td>\n<\/tr>\n
Spiriva Handihaler (tiotropium)<\/span><\/td>\nCOPD maintenance treatment<\/span><\/td>\n2 inhalations (18 mcg) once daily<\/span><\/td>\nSpiriva coupons<\/span><\/a><\/td>\n<\/tr>\n
Advair Diskus (fluticasone\/ salmeterol)<\/span><\/td>\nAsthma maintenance treatment, Chronic obstructive pulmonary disease (COPD)<\/span><\/td>\n1 inhalation (250\/50 mcg) twice daily in the morning and evening<\/span><\/td>\nAdvair Diskus coupons<\/span><\/a><\/td>\n<\/tr>\n
Incruse Ellipta (umeclidinium)<\/span><\/td>\nCOPD maintenance treatment<\/span><\/td>\n1 actuation (62.5 mcg) by mouth once daily<\/span><\/td>\nIncruse Ellipta coupons<\/span><\/a><\/td>\n<\/tr>\n
Trelegy Ellipta (fluticasone\/ umeclidinium\/ vilanterol)<\/span><\/td>\nAsthma maintenance treatment, Chronic obstructive pulmonary disease (COPD)<\/span><\/td>\n1 inhalation (100\/62.5\/25 mcg) by mouth once daily<\/span><\/td>\nTrelegy Ellipta coupons<\/span><\/a><\/td>\n<\/tr>\n
Mucomyst (acetylcysteine)<\/span><\/td>\nCOPD adjunct treatment, mucus thinning<\/span><\/td>\n3 to 5 ml of the 20% solution nebulized 3-4 times daily<\/span><\/td>\nMucomyst coupons<\/span><\/a><\/td>\n<\/tr>\n
Ventolin\/ Proventil (albuterol)<\/span><\/td>\nAsthma exacerbation, bronchospasm<\/span><\/td>\n2 puffs (90 mcg each) every 4-6 hours<\/span><\/td>\nVentolin coupons<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Other alternatives to Bevespi<\/span><\/h3>\n